Landscape Capital Management L.L.C. Buys New Shares in Insulet Corporation $PODD

Landscape Capital Management L.L.C. bought a new stake in Insulet Corporation (NASDAQ:PODD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,675 shares of the medical instruments supplier’s stock, valued at approximately $5,877,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in Insulet during the 4th quarter valued at $28,000. Fideuram Asset Management Ireland dac acquired a new stake in Insulet during the 4th quarter valued at $41,000. Measured Wealth Private Client Group LLC acquired a new stake in Insulet during the 3rd quarter valued at $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in Insulet during the 2nd quarter valued at $51,000.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.36% of the company’s stock.

Insulet Stock Up 0.3%

PODD opened at $149.70 on Friday. Insulet Corporation has a fifty-two week low of $140.63 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The company has a market capitalization of $10.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 1.18 and a beta of 1.13. The stock has a fifty day moving average of $169.92 and a 200-day moving average of $232.67.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the firm earned $1.02 earnings per share. The company’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts expect that Insulet Corporation will post 6.46 EPS for the current year.

Analysts Set New Price Targets

PODD has been the subject of several research reports. Bank of America cut their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. BTIG Research cut their price target on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $280.00 price target on shares of Insulet in a report on Wednesday, May 27th. Finally, Weiss Ratings downgraded Insulet from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.